MCID: PTH002
MIFTS: 51

Pathological Gambling malady

Categories: Mental diseases

Aliases & Classifications for Pathological Gambling

Aliases & Descriptions for Pathological Gambling:

Name: Pathological Gambling 12 14
Compulsive Gambling 12 41
Gambling, Pathological 69
Gambling 42

Classifications:



External Ids:

Disease Ontology 12 DOID:12399
ICD10 33 F63.0
ICD9CM 35 312.31
MeSH 42 D005715
NCIt 47 C94335
UMLS 69 C0030662

Summaries for Pathological Gambling

MedlinePlus : 41 many people enjoy gambling, whether it's betting on a horse or playing poker on the internet. most people who gamble don't have a problem, but some lose control of their gambling. signs of problem gambling include always thinking about gambling lying about gambling spending work or family time gambling feeling bad after you gamble, but not quitting gambling with money you need for other things if you have concerns about your gambling, ask for help. your health care provider can work with you to find the treatment that's best for you. nih: national institutes of health

MalaCards based summary : Pathological Gambling, also known as compulsive gambling, is related to personality disorder and schizophrenia. An important gene associated with Pathological Gambling is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Signaling in Gap Junctions. The drugs Topiramate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 An impulse control disorder that involves the uncontrollable impulse to gamble, irrespective of the interference the behaviour has on the individual's life.

Related Diseases for Pathological Gambling

Diseases related to Pathological Gambling via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
id Related Disease Score Top Affiliating Genes
1 personality disorder 28.8 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
2 schizophrenia 28.1 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
3 congenital chloride diarrhea 11.4
4 schizoid personality disorder 10.2 DRD3 SLC6A4
5 sphenoorbital meningioma 10.1 DRD2 DRD3 DRD4
6 intracranial aneurysm 10.1 DRD2 DRD3 DRD4
7 benign partial epilepsy with secondarily generalized seizures in infancy 10.1 DRD3 SLC6A3
8 scoliosis 10.1 DRD2 SLC6A3
9 anodontia 10.1 SLC6A3 SLC6A4
10 obsessive-compulsive disorder 10.1
11 apperceptive agnosia 10.1 DRD2 SLC6A4
12 18p deletion syndrome 10.1 DRD2 DRD4 SLC6A3
13 usher syndrome 10.1 DRD2 DRD3 SLC6A3
14 rectosigmoid junction neoplasm 10.1 DRD2 DRD4 SLC6A3
15 nephronophthisis 13 10.1 HTR2A SLC6A4
16 dry eye syndrome 10.1 HTR2A SLC6A4
17 cavernous hemangioma 10.1 DRD2 DRD3 SLC6A3
18 teratoma with malignant transformation 10.1 DRD2 DRD3 HTR2A
19 aortic valve disease 2 10.1 DRD2 DRD4 SLC6A3
20 allergic hypersensitivity disease 10.0 DRD2 HTR2A
21 intracranial cavernous angioma 10.0 DRD2 SLC6A3 SLC6A4
22 adult brainstem astrocytoma 10.0 MAOA SLC6A4
23 vascular cancer 10.0 DRD2 HTR2A
24 renpenning syndrome 10.0 MAOA SLC6A4
25 cholesteatoma 10.0 DRD2 SLC6A3 SLC6A4
26 autism spectrum disorder 10.0 DRD4 SLC6A3 SLC6A4
27 kidney pelvis papillary carcinoma 10.0 MAOA SLC6A4
28 euthyroid sick syndrome 10.0 DRD2 HTR2A SLC6A4
29 waardenburg's syndrome 10.0 DRD2 HTR2A SLC6A4
30 c8 deficiency, type ii 10.0 DRD1 DRD2 DRD3 DRD4
31 alcohol dependence 9.9
32 ornithosis 9.9 DRD2 MAOA SLC6A4
33 alopecia 9.9 DRD2 DRD3 DRD4 SLC6A4
34 primary angle-closure glaucoma 9.9 DRD1 HTR2A SLC6A4
35 tinea pedis 9.9 MAOA SLC6A3 SLC6A4
36 transmitted_by 9.9 DRD2 DRD3 SLC6A3 SLC6A4
37 lethal congenital contracture syndrome 1 9.9 MAOA MAOB
38 dementia 9.9
39 cocaine dependence 9.9
40 hypoglycemia 9.9 DRD1 DRD2 DRD3 SLC6A4
41 tuberculoid leprosy 9.9 MAOA MAOB
42 neurogenic bladder 9.9 HTR2A MAOA SLC6A4
43 chronic eosinophilic pneumonia 9.9 MAOA SLC6A4
44 autism 19 9.9 DRD2 MAOB SLC6A3
45 alzheimer disease 17 9.9 DRD3 DRD4 HTR2A SLC6A4
46 intrahepatic gall duct cancer 9.9 HTR2A MAOA SLC6A4
47 hypoglycemic coma 9.9 HTR2A MAOA SLC6A4
48 multiple personality disorder 9.9 HTR2A MAOA SLC6A4
49 keratosis 9.9 HTR2A MAOA SLC6A4
50 lichen disease 9.8 HTR2A MAOA SLC6A4

Graphical network of the top 20 diseases related to Pathological Gambling:



Diseases related to Pathological Gambling

Symptoms & Phenotypes for Pathological Gambling

GenomeRNAi Phenotypes related to Pathological Gambling according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 MAOB DRD1 DRD2 DRD3 DRD4 HTR2A

MGI Mouse Phenotypes related to Pathological Gambling:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 MAOB SLC6A3 SLC6A4 DRD1 DRD2 DRD3
2 homeostasis/metabolism MP:0005376 9.76 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
3 muscle MP:0005369 9.35 DRD1 DRD2 HTR2A SLC6A3 SLC6A4
4 nervous system MP:0003631 9.23 DRD1 DRD2 DRD3 DRD4 MAOA MAOB

Drugs & Therapeutics for Pathological Gambling

Drugs for Pathological Gambling (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
2
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4 59-92-7 6047
4
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
5
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3 6740-88-1 3821
6
Nicotine Approved Phase 4,Phase 2 54-11-5 942 89594
7
Etidronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 7414-83-7, 2809-21-4 3305
8
Alendronate Approved Phase 4,Phase 2,Phase 1 121268-17-5, 66376-36-1 2088
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
10
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
11
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
14
Ephedrine Approved Phase 4 299-42-3 9294
15
Pseudoephedrine Approved Phase 4 90-82-4 7028
16
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
17
Carbon monoxide Approved Phase 4 630-08-0 281
18
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
19
Histamine Approved, Investigational Phase 4,Phase 1 75614-87-8, 51-45-6 774
20
Promethazine Approved Phase 4 60-87-7 4927
21
Desonide Approved, Investigational Phase 4 638-94-8 5311066
22
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
23
Darifenacin Approved, Investigational Phase 4,Phase 1 133099-04-4 444031
24
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
25
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
26
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
27
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
28
Loperamide Approved Phase 4 53179-11-6 3955
29
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
30
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
31
Tetrabenazine Approved Phase 4 58-46-8 6018
32
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
33
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
34
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
36
Creatine Approved, Nutraceutical Phase 4 57-00-1 586
37
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
38
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
39
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
40
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
41 Anticonvulsants Phase 4,Phase 3,Phase 2
42 Anti-Obesity Agents Phase 4,Phase 2
43 Neuroprotective Agents Phase 4,Phase 3,Phase 2
44 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Dihydroxyphenylalanine Phase 4
47 Dopamine Agents Phase 4,Phase 3,Phase 2
48 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Central Nervous System Stimulants Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 337)
id Name Status NCT ID Phase
1 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
2 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
3 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4
4 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4
5 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4
6 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4
7 An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity Completed NCT02476032 Phase 4
8 Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression Completed NCT00903448 Phase 4
9 Prophylactic Ephedrine and Combined Spinal Epidurals for Labor Completed NCT02062801 Phase 4
10 A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing Completed NCT00855933 Phase 4
11 Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression Completed NCT00808769 Phase 4
12 Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Completed NCT01935115 Phase 4
13 Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic Completed NCT01050556 Phase 4
14 Polyherbal Capsule Formulation for Joint Health Completed NCT02157701 Phase 4
15 Neuropsychological Prognosis Factors of Smoking Cessation Completed NCT01554436 Phase 4
16 Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness Completed NCT02578186 Phase 4
17 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4
18 Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate Completed NCT00837746 Phase 4
19 A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory Completed NCT01404130 Phase 4
20 Effects of a Polyherbal Supplement on the Signs and Symptoms of Delayed Onset Muscle Soreness Completed NCT02157675 Phase 4
21 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4
22 POWER Point of Care Effect on Satisfaction of Treatment Completed NCT00549068 Phase 4
23 SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture. Completed NCT00460733 Phase 4
24 Risedronate Sodium in Post Menopausal Osteoporosis Completed NCT00453492 Phase 4
25 Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects Completed NCT00413790 Phase 4
26 Risedronate in the Prevention of Osteoporosis in Postmenopausal Women Completed NCT00402441 Phase 4
27 Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Completed NCT00366002 Phase 4
28 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4
29 Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder Completed NCT00171184 Phase 4
30 OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women Completed NCT00130403 Phase 4
31 Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder Completed NCT00127270 Phase 4
32 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4
33 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4
34 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
35 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed NCT00869622 Phase 4
36 Evaluation of a Handwashing Promotion Program in Chinese Elementary Schools Completed NCT00140335 Phase 4
37 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
38 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Recruiting NCT01749215 Phase 4
39 A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) Recruiting NCT02509793 Phase 4
40 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Recruiting NCT01733199 Phase 4
41 The Relationship Between Common Psychiatric Drugs and Stress, and Their Influence on Cognitive Functions in Healthy and Sub-clinically Anxious Populations Not yet recruiting NCT02862236 Phase 4
42 Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects Terminated NCT01582282 Phase 4
43 Bone Microarchitecture in Osteopenic Postmenopausal Women Terminated NCT00577395 Phase 4
44 Surveillance Study of Women Taking Intrinsa® Terminated NCT00551785 Phase 4
45 ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week Terminated NCT00544180 Phase 4
46 Acute Cough Study In Children Terminated NCT01257542 Phase 4
47 An Open Prospective Trial of IV Ketamine in Suicidal Adolescents Unknown status NCT02048423 Phase 2, Phase 3
48 The IMAP Study Improving Management of Mildly Abnormal Pap Smears Unknown status NCT00119509 Phase 3
49 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3
50 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3

Search NIH Clinical Center for Pathological Gambling

Cochrane evidence based reviews: gambling

Genetic Tests for Pathological Gambling

Anatomical Context for Pathological Gambling

MalaCards organs/tissues related to Pathological Gambling:

39
Brain, Cortex, Prefrontal Cortex, Subthalamic Nucleus, Testes, Pituitary, Skin

Publications for Pathological Gambling

Articles related to Pathological Gambling:

(show top 50) (show all 570)
id Title Authors Year
1
Personality disorders and pathological gambling. ( 27798487 )
2017
2
Prevalence of pathological gambling in patients with alcohol dependence syndrome attending a tertiary care center in South India. ( 28483101 )
2017
3
Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating. ( 27882998 )
2016
4
Pathological gambling: a review of the neurobiological evidence relevant for its classification as an addictive disorder. ( 26935000 )
2016
5
Assessing the effects of cocaine dependence and pathological gambling using group-wise sparse representation of natural stimulus FMRI data. ( 27704410 )
2016
6
Genome-wide association study of pathological gambling. ( 27315593 )
2016
7
Impulsivity, implicit attitudes and explicit cognitions, and alcohol dependence as predictors of pathological gambling. ( 27614152 )
2016
8
Pathological Gambling in Parkinson's disease patients: Dopaminergic medication or personality traits fault? ( 27288799 )
2016
9
Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity? ( 27623191 )
2016
10
The association between pathological gambling and suicidality in treatment-seeking pathological gamblers in South Africa. ( 26855985 )
2016
11
Pathological Gambling and Associated Drug and Alcohol Abuse, Emotion Regulation, and Anxious-Depressive Symptomatology. ( 27348555 )
2016
12
Development and validation of the Gambling Follow-up Scale, Self-Report version: an outcome measure in the treatment of pathological gambling. ( 27828667 )
2016
13
Predictability in Pathological Gambling? Applying the Duplication of Purchase Law to the Understanding of Cross-Purchases Between Regular and Pathological Gamblers. ( 27328818 )
2016
14
Pathological gambling: a behavioral addiction. ( 27717269 )
2016
15
Intergenerational Childhood Maltreatment in Persons with DSM-IV Pathological Gambling and Their First-Degree Relatives. ( 26749583 )
2016
16
A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. ( 26339899 )
2016
17
A Preliminary Study of DBH (Encoding Dopamine Beta-Hydroxylase) Genetic Variation and Neural Correlates of Emotional and Motivational Processing in Individuals With and Without Pathological Gambling. ( 27194378 )
2016
18
Cognitive distortions and ADHD in pathological gambling: A national longitudinal case-control cohort study. ( 27774813 )
2016
19
Frontal cortex gray matter volume alterations in pathological gambling occur independently from substance use disorder. ( 26771165 )
2016
20
Effects of High Frequency Repeated Transcranial Magnetic Stimulation and Continuous Theta Burst Stimulation on Gambling Reinforcement, Delay Discounting, and Stroop Interference in Men with Pathological Gambling. ( 27350401 )
2016
21
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. ( 26658263 )
2016
22
Treatment of pathological gambling - integrative systemic model. ( 25751445 )
2015
23
Parental bonding in subjects with pathological gambling disorder compared with healthy controls. ( 25447192 )
2015
24
Sexual abuse, residential schooling and probable pathological gambling among Indigenous Peoples. ( 25816756 )
2015
25
Increased impulsivity in pathological gambling: Considering nicotine dependence. ( 25819174 )
2015
26
Predicting treatment failure in pathological gambling: the role of personality traits. ( 25555154 )
2015
27
Working memory, executive function and impulsivity in Internet-addictive disorders: a comparison with pathological gambling. ( 26400106 )
2015
28
Should pathological gambling and obesity be considered addictive disorders? A factor analytic study in a nationally representative sample. ( 25769392 )
2015
29
Age at onset of DSM-IV pathological gambling in a non-treatment sample: Early- versus later-onset. ( 25956751 )
2015
30
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
31
Piribedil and pathological gambling in six parkinsonian patients. ( 25742580 )
2015
32
Neurobiological correlates of internet gaming disorder: Similarities to pathological gambling. ( 26621112 )
2015
33
Increased corticolimbic connectivity in cocaine dependence versus pathological gambling is associated with drug severity and emotion-related impulsivity. ( 25818325 )
2015
34
Hypothalamic-pituitary-adrenal axis activity in patients with pathological gambling and internet use disorder. ( 25619430 )
2015
35
The relationship of DSM-IV pathological gambling to compulsive buying and other possible spectrum disorders: Results from the Iowa PG family study. ( 25660732 )
2015
36
The Role of Metacognition in Pathological Gambling: A Mediation Model. ( 25600034 )
2015
37
Masochism and pathological gambling. ( 25734872 )
2015
38
Suicide Ideations, Suicide Attempts, and Completed Suicide in Persons with Pathological Gambling and Their First-Degree Relatives. ( 25845522 )
2015
39
Thresholds of probable problematic gambling involvement for the German population: Results of the Pathological Gambling and Epidemiology (PAGE) Study. ( 26415065 )
2015
40
Associations between obsessive-compulsive classes and pathological gambling in a national cohort of male twins. ( 25671842 )
2015
41
Towards a Validation of the Three Pathways Model of Pathological Gambling. ( 25980378 )
2015
42
Towards a comprehensive developmental model of pathological gambling. ( 25879250 )
2015
43
Heterogeneity of Loss Aversion in Pathological Gambling. ( 26711104 )
2015
44
Pathological gambling associated with CADASIL: an unusual manifestation. ( 26142163 )
2015
45
The "Pathological Gambling and Epidemiology" (PAGE) study program: design and fieldwork. ( 25583586 )
2015
46
Correction: Increased Functional Connectivity between Prefrontal Cortex and Reward System in Pathological Gambling. ( 26196675 )
2015
47
Discussion of masochism and pathological gambling: a review of masochism. ( 25734873 )
2015
48
Early-onset frontotemporal dementia presenting with pathological gambling. ( 25682087 )
2015
49
Pathological Gambling Due to Aripiprazole: Two Cases. ( 27617507 )
2015
50
Metacognition in Pathological Gambling and Its Relationship with Anxious and Depressive Symptomatology. ( 25962856 )
2015

Variations for Pathological Gambling

Expression for Pathological Gambling

Search GEO for disease gene expression data for Pathological Gambling.

Pathways for Pathological Gambling

Pathways related to Pathological Gambling according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 DRD1 DRD2 DRD3 DRD4
2
Show member pathways
12.17 DRD1 DRD2 HTR2A
3 12.13 DRD1 DRD2 DRD3 DRD4
4
Show member pathways
11.98 DRD1 DRD2 DRD4
6 11.96 HTR2A MAOA SLC6A4
7
Show member pathways
11.83 DRD1 DRD2 DRD3 DRD4 MAOA MAOB
8 11.69 DRD3 DRD4 HTR2A
9
Show member pathways
11.68 DRD2 DRD3 DRD4
10 11.68 HTR2A MAOA MAOB SLC6A4
11
Show member pathways
11.62 DRD1 DRD2 MAOA MAOB SLC6A3
12
Show member pathways
11.41 DRD1 DRD2 DRD3 DRD4 HTR2A
13
Show member pathways
11.27 MAOA SLC6A3 SLC6A4
14
Show member pathways
11.14 MAOA MAOB
15 11.09 MAOB SLC6A3
16 11.06 HTR2A MAOA SLC6A4
17
Show member pathways
11.01 MAOA SLC6A3 SLC6A4
18 10.94 DRD1 DRD2 DRD3
19 10.69 MAOA MAOB
20
Show member pathways
10.68 MAOA MAOB
21
Show member pathways
10.64 MAOA MAOB

GO Terms for Pathological Gambling

Cellular components related to Pathological Gambling according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.91 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
2 integral component of membrane GO:0016021 9.61 DRD1 DRD2 DRD3 DRD4 HTR2A MAOA
3 axon GO:0030424 9.5 DRD2 HTR2A SLC6A3
4 ciliary membrane GO:0060170 9.37 DRD1 DRD2
5 integral component of plasma membrane GO:0005887 9.17 DRD1 DRD2 DRD3 DRD4 HTR2A SLC6A3
6 non-motile cilium GO:0097730 9.16 DRD1 DRD2

Biological processes related to Pathological Gambling according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.88 DRD2 DRD3 MAOB SLC6A3
2 response to toxic substance GO:0009636 9.85 DRD2 MAOB SLC6A4
3 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 HTR2A
4 locomotory behavior GO:0007626 9.84 DRD1 DRD2 DRD3 SLC6A3
5 memory GO:0007613 9.81 DRD1 HTR2A SLC6A4
6 social behavior GO:0035176 9.8 DRD3 DRD4 SLC6A4
7 visual learning GO:0008542 9.8 DRD1 DRD2 DRD3
8 negative regulation of adenylate cyclase activity GO:0007194 9.77 DRD2 DRD3 DRD4
9 arachidonic acid secretion GO:0050482 9.76 DRD2 DRD3 DRD4
10 response to cocaine GO:0042220 9.76 DRD1 DRD2 DRD3 SLC6A3
11 regulation of dopamine secretion GO:0014059 9.74 DRD2 DRD3 HTR2A
12 neurotransmitter transport GO:0006836 9.73 SLC6A3 SLC6A4
13 feeding behavior GO:0007631 9.73 DRD1 DRD2
14 response to nicotine GO:0035094 9.73 DRD2 SLC6A3
15 release of sequestered calcium ion into cytosol GO:0051209 9.73 DRD2 HTR2A
16 negative regulation of protein kinase B signaling GO:0051898 9.73 DRD2 DRD3
17 temperature homeostasis GO:0001659 9.73 DRD1 DRD2 HTR2A
18 positive regulation of cytokinesis GO:0032467 9.72 DRD2 DRD3
19 positive regulation of multicellular organism growth GO:0040018 9.72 DRD2 SLC6A3
20 adult walking behavior GO:0007628 9.72 DRD1 DRD2
21 negative regulation of blood pressure GO:0045776 9.72 DRD2 DRD3
22 response to morphine GO:0043278 9.72 DRD2 DRD3
23 synaptic transmission, dopaminergic GO:0001963 9.72 DRD1 DRD2 DRD3
24 associative learning GO:0008306 9.71 DRD1 DRD2
25 behavioral fear response GO:0001662 9.71 DRD1 DRD4
26 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
27 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
28 response to amphetamine GO:0001975 9.71 DRD1 DRD2 DRD3 DRD4
29 behavioral response to ethanol GO:0048149 9.7 DRD2 DRD4
30 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A3 SLC6A4
31 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD2 HTR2A
32 grooming behavior GO:0007625 9.7 DRD1 DRD2
33 negative regulation of protein secretion GO:0050709 9.7 DRD2 DRD3 DRD4
34 ammonium transmembrane transport GO:0072488 9.69 SLC6A3 SLC6A4
35 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
36 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.69 DRD1 DRD2
37 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD3 DRD4
38 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD2 DRD4
39 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
40 striatum development GO:0021756 9.68 DRD1 DRD2
41 neurotransmitter catabolic process GO:0042135 9.67 MAOA MAOB
42 peristalsis GO:0030432 9.67 DRD1 DRD2
43 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD1 DRD3
44 regulation of dopamine metabolic process GO:0042053 9.67 DRD1 DRD4 SLC6A3
45 adenohypophysis development GO:0021984 9.66 DRD2 SLC6A3
46 monoamine transport GO:0015844 9.65 SLC6A3 SLC6A4
47 regulation of cAMP metabolic process GO:0030814 9.65 DRD2 DRD3
48 dopamine transport GO:0015872 9.65 DRD1 SLC6A3
49 dopamine catabolic process GO:0042420 9.65 MAOA MAOB SLC6A3
50 cerebral cortex GABAergic interneuron migration GO:0021853 9.64 DRD1 DRD2

Molecular functions related to Pathological Gambling according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 DRD1 DRD2 DRD3 DRD4 HTR2A
2 signal transducer activity GO:0004871 9.72 DRD1 DRD2 DRD3 DRD4 HTR2A
3 drug binding GO:0008144 9.55 DRD2 DRD3 DRD4 HTR2A SLC6A3
4 neurotransmitter:sodium symporter activity GO:0005328 9.48 SLC6A3 SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3 DRD4
7 primary amine oxidase activity GO:0008131 9.4 MAOA MAOB
8 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD1 DRD2 DRD3 DRD4
10 dopamine binding GO:0035240 9.02 DRD1 DRD2 DRD3 DRD4 SLC6A3

Sources for Pathological Gambling

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....